News Releases

Sep 11, 2020
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
- Stephen Dilly to resign from the Sangamo board effective September 30, 2020 BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan , an accomplished biotechnology executive,
Additional Formats
Displaying 1 - 10 of 28